Emergent BioSolutions Inc. (EBS)

Market Cap	601.44M
Revenue (ttm)	1.13B
Net Income (ttm)	-208.80M
Shares Out	54.18M
EPS (ttm)	-3.98
PE Ratio	n/a
Forward PE	6.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,994
Open	11.03
Previous Close	10.80
Day's Range	10.92 - 11.19
52-Week Range	1.42 - 15.10
Beta	1.60
Analysts	Strong Buy
Price Target	14.33 (+29.1%)
Earnings Date	Mar 4, 2025

About EBS

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 15, 2006
• Employees: 1,600
• Stock Exchange: NYSE
• Ticker Symbol: EBS
• Website: https://www.emergentbiosolutions.com

Financial Performance

In 2023, Emergent BioSolutions's revenue was $1.05 billion, a decrease of -6.10% compared to the previous year's $1.12 billion. Losses were -$760.50 million, 259.4% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for EBS stock is "Strong Buy." The 12-month stock price forecast is $14.33, which is an increase of 29.10% from the latest price.

Price Target

$14.33

(29.10% upside)

Analyst Consensus: Strong Buy